Phathom Operating Margin from 2010 to 2026
| PHAT Stock | USD 12.02 0.21 1.72% |
Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 18.3 M, Depreciation And Amortization of 635.5 K or Interest Expense of 87 M, as well as many indicators such as Price To Sales Ratio of 10.14, Dividend Yield of 0.0 or Days Sales Outstanding of 280. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.
Phathom | Operating Margin | Build AI portfolio with Phathom Stock |
The evolution of Operating Margin for Phathom Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Phathom Pharmaceuticals compares to historical norms and industry peers.
Latest Phathom Pharmaceuticals' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Phathom Pharmaceuticals over the last few years. It is Phathom Pharmaceuticals' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Phathom Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.31) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Phathom Operating Margin Regression Statistics
| Arithmetic Mean | (202.87) | |
| Coefficient Of Variation | (46.60) | |
| Mean Deviation | 69.92 | |
| Median | (245.33) | |
| Standard Deviation | 94.53 | |
| Sample Variance | 8,936 | |
| Range | 241 | |
| R-Value | 0.66 | |
| Mean Square Error | 5,361 | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 12.38 | |
| Total Sum of Squares | 142,973 |
Phathom Operating Margin History
About Phathom Pharmaceuticals Financial Statements
Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.